News | August 30, 2021
Granules India receives approval from Health Canada for arthritis drug
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
Acetaminophen extended-release tablets 650 mg is bioequivalent of the reference listed drug Tylenol
India is dependent upon China and other countries for a lot of Key Starting Materials (KSM) for their bulk drug needs.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The US FDA has closed the observations pertaining to this audit with an Establishment Inspection Report on the 20th of July 2021
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The company will provide one crore tablets every week, starting from 12th May 2021, aggregating to 16 crore tablets worth Rs. 8 crores over the next 4 months
ranules now has a total of 38 ANDA approvals from US FDA.
Granules now has a total of 37 ANDA approvals from US FDA (36 Final approvals and 1 tentative approvals).
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
Subscribe To Our Newsletter & Stay Updated
